Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081094788> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3081094788 abstract "RO7049389, an inhibitor of hepatitis B virus (HBV) capsid assembly, is being developed for the treatment of patients with chronic HBV infection. The objectives of this first-in-human study are to assess the safety, tolerability, pharmacokinetics (PK), food effect, inhibitory effect on CYP3A, and effect on QT of RO7049389 in healthy participants. Five components, single-ascending-dose (SAD) cohorts, multiple-ascending-dose (MAD) cohorts, food effect assessment, drug-drug interaction assessment, and concentration-QT analysis were integrated in one study (five-in-one). Participants randomly received a single dose of 150 to 2,500 mg RO7049389 or placebo in SAD cohorts (n = 41), or multiple doses of 200 to 800 mg RO7049389 or placebo in MAD cohorts (n = 42). A single doses of 450 mg RO7049389 was administered under fasted and fed condition. The microdose of midazolam was administered before and after multiple dosing of RO7049389. Safety and tolerability were monitored throughout the study. Serial blood and urine samples were collected for the PK analysis. RO7049389 was safe and well tolerated in healthy participants. Absorption and elimination of RO7049389 occurred rapidly in plasma with minimal recovery in urine. Greater than dose-proportional increases in plasma exposure were observed. Exposure of RO7049389 (450 mg) increased by ∼2-fold when administered with a high-fat meal. The inhibition effect of RO7049389 on CYP3A was weak (<20%). No effect on QT interval was observed at up to a single dose of 2,500 mg. RO7049389 displayed a favorable safety, tolerability and PK profile suitable for further clinical development. (This trial was registered at ClinicalTrials.gov with the identifier NCT02952924.)." @default.
- W3081094788 created "2020-09-01" @default.
- W3081094788 creator A5028045704 @default.
- W3081094788 creator A5038566539 @default.
- W3081094788 creator A5038656678 @default.
- W3081094788 creator A5043659609 @default.
- W3081094788 creator A5077329607 @default.
- W3081094788 creator A5082033852 @default.
- W3081094788 creator A5088842832 @default.
- W3081094788 creator A5088890103 @default.
- W3081094788 date "2020-10-20" @default.
- W3081094788 modified "2023-10-01" @default.
- W3081094788 title "A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants" @default.
- W3081094788 cites W2093256025 @default.
- W3081094788 cites W2605785536 @default.
- W3081094788 cites W2799657926 @default.
- W3081094788 cites W4240582591 @default.
- W3081094788 doi "https://doi.org/10.1128/aac.01323-20" @default.
- W3081094788 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7577148" @default.
- W3081094788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32839221" @default.
- W3081094788 hasPublicationYear "2020" @default.
- W3081094788 type Work @default.
- W3081094788 sameAs 3081094788 @default.
- W3081094788 citedByCount "15" @default.
- W3081094788 countsByYear W30810947882021 @default.
- W3081094788 countsByYear W30810947882022 @default.
- W3081094788 countsByYear W30810947882023 @default.
- W3081094788 crossrefType "journal-article" @default.
- W3081094788 hasAuthorship W3081094788A5028045704 @default.
- W3081094788 hasAuthorship W3081094788A5038566539 @default.
- W3081094788 hasAuthorship W3081094788A5038656678 @default.
- W3081094788 hasAuthorship W3081094788A5043659609 @default.
- W3081094788 hasAuthorship W3081094788A5077329607 @default.
- W3081094788 hasAuthorship W3081094788A5082033852 @default.
- W3081094788 hasAuthorship W3081094788A5088842832 @default.
- W3081094788 hasAuthorship W3081094788A5088890103 @default.
- W3081094788 hasBestOaLocation W30810947882 @default.
- W3081094788 hasConcept C112705442 @default.
- W3081094788 hasConcept C126322002 @default.
- W3081094788 hasConcept C142724271 @default.
- W3081094788 hasConcept C197934379 @default.
- W3081094788 hasConcept C204787440 @default.
- W3081094788 hasConcept C27081682 @default.
- W3081094788 hasConcept C2777288759 @default.
- W3081094788 hasConcept C2778375690 @default.
- W3081094788 hasConcept C71924100 @default.
- W3081094788 hasConcept C98274493 @default.
- W3081094788 hasConceptScore W3081094788C112705442 @default.
- W3081094788 hasConceptScore W3081094788C126322002 @default.
- W3081094788 hasConceptScore W3081094788C142724271 @default.
- W3081094788 hasConceptScore W3081094788C197934379 @default.
- W3081094788 hasConceptScore W3081094788C204787440 @default.
- W3081094788 hasConceptScore W3081094788C27081682 @default.
- W3081094788 hasConceptScore W3081094788C2777288759 @default.
- W3081094788 hasConceptScore W3081094788C2778375690 @default.
- W3081094788 hasConceptScore W3081094788C71924100 @default.
- W3081094788 hasConceptScore W3081094788C98274493 @default.
- W3081094788 hasIssue "11" @default.
- W3081094788 hasLocation W30810947881 @default.
- W3081094788 hasLocation W30810947882 @default.
- W3081094788 hasLocation W30810947883 @default.
- W3081094788 hasOpenAccess W3081094788 @default.
- W3081094788 hasPrimaryLocation W30810947881 @default.
- W3081094788 hasRelatedWork W1830687917 @default.
- W3081094788 hasRelatedWork W1966047811 @default.
- W3081094788 hasRelatedWork W2003042623 @default.
- W3081094788 hasRelatedWork W202460821 @default.
- W3081094788 hasRelatedWork W2037651778 @default.
- W3081094788 hasRelatedWork W2064759457 @default.
- W3081094788 hasRelatedWork W2074207917 @default.
- W3081094788 hasRelatedWork W3087516196 @default.
- W3081094788 hasRelatedWork W3131642206 @default.
- W3081094788 hasRelatedWork W3160956384 @default.
- W3081094788 hasVolume "64" @default.
- W3081094788 isParatext "false" @default.
- W3081094788 isRetracted "false" @default.
- W3081094788 magId "3081094788" @default.
- W3081094788 workType "article" @default.